Expression and clinical significance of SNF5 in bladder cancer

Hua DING; Liwei WANG; Jingqi ZHANG; Xiaozhou ZHOU; Zhiwen CHEN

doi:10.16016/j.1000-5404.202008004

您当前的位置：

首页 >

文章列表页 >

Expression and clinical significance of SNF5 in bladder cancer

Clinical Medicine | 更新时间：2026-01-09

- Expression and clinical significance of SNF5 in bladder cancer
- Journal of Third Military Medical University Vol. 42, Issue 24, Pages: 2408-2412(2020)
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)第一附属医院泌尿外科
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.202008004
  CLC： R394.3;R730.23;R737.14
- Received：03 August 2020，
  
  Revised：2020-09-07，
  
  Published：30 December 2020
- 稿件说明：
移动端阅览
Hua DING, Liwei WANG, Jingqi ZHANG, et al. Expression and clinical significance of SNF5 in bladder cancer[J]. Journal of Third Military Medical University, 2020, 42(24): 2408-2412.
DOI：

Hua DING, Liwei WANG, Jingqi ZHANG, et al. Expression and clinical significance of SNF5 in bladder cancer[J]. Journal of Third Military Medical University, 2020, 42(24): 2408-2412. DOI： 10.16016/j.1000-5404.202008004.

摘要

目的

探讨SNF5在膀胱癌中的表达水平及临床意义。

方法

分别利用癌症基因组图谱数据库(the Cancer Genome Atlas，TCGA)分析RNA-seq数据、qPCR检测膀胱癌细胞系，研究膀胱癌中SNF5表达水平，并结合TCGA临床样本信息行Kaplan-Meier生存分析研究SNF5对预后的影响。收集2012年1月至2018年12月我科收治的157例膀胱癌患者肿瘤组织及临床信息，免疫组化法检测膀胱癌组织中SNF5蛋白水平，分析其与临床病理特征关系。

结果

在mRNA水平，SNF5在膀胱癌组织中和膀胱癌细胞系中均高于正常膀胱组织，在不同mRNA膀胱癌亚型和膀胱癌细胞系中表达也存在差异。生存分析中提示SNF5 mRNA低表达组患者总体生存时间明显缩短(

0.01)，而Cox分析进一步提示SNF5是膀胱癌独立预后因素。在蛋白水平，回顾性研究发现SNF5表达水平与肌层浸润(

0.01)、淋巴结阳性(

0.01)密切相关。

结论

SNF5在膀胱癌中表达上调，与膀胱癌发生、发展及预后密切相关，具有作为潜在治疗靶点的潜能。

Abstract

Objective

To explore the expression and clinical significance of SNF5 in bladder cancer.

Methods

Based on the data from the Cancer Genome Atlas (TCGA) database

SNF5 mRNA level from 408 cases of bladder cancer tissues and 19 cases of normal bladder tissues were retrieved and analyzed with clinical data. Kaplan-Meier analysis was employed to study the relationship between SNF5 level and survival rate in these bladder cancer patients. qPCR was performed to determine the expression level of SNF5 in different bladder cancer cell lines (5637

T24

RT4

UM-UC-3

TCCSUP

J82) and normal human urothelial cell line SV-HUC-1. What's more

the protein expression of SNF5 in clinically collected bladder cancer samples (from 157 patients admitted in our hospital from January 2012 to December 2018) was detected by immunohistochemical (IHC) assay

and its association with clinicopathological features was analyzed with Cox regression analysis.

Results

The mRNA expression of SNF5 was higher in both bladder cancer tissues and cell lines than normal bladder tissues and cells

and the expression variations were significant among different subtypes of bladder cancer and cancer cell lines. The results of Kaplan-Meier analysis indicated that the patients with lower SNF5 mRNA level had worse prognosis than those with higher expression (

0.01). Cox regression analysis showed SNF5 was an independent prognostic factor for bladder cancer. The protein level of SNF5 was significantly correlated with myometrial infiltration (

0.01) and lymph node metastasis (

0.01).

Conclusion

SNF5 is upregulated in bladder cancer

and closely associated with its incidence

progression and prognosis. It may be used as a promising therapeutic target in treatment for bladder cancer.

关键词

Keywords

references

SHI H, JIANG H, WANG L, et al . Overexpression of monocarboxylate anion transporter 1 and 4 in T24-induced cancer-associated fibroblasts regulates the progression of bladder cancer cells in a 3D microfluidic device[J ] . Cell Cycle, 2015, 14(19): 3058-3065. DOI: 10.1080/15384101.2015.1053666.

HUANG C, LIAO X, JIN H, et al . MEG3, as a competing endogenous RNA , binds with miR-27a to promote PHLPP2 protein translation and impairs bladder cancer invasion[J ] . Mol Ther Nucleic Acids, 2019, 16: 51-62. DOI: 10.1016/j.omtn.2019.01.014.

CAO R, YUAN L, MA B, et al . An EMT-related gene signature for the prognosis of human bladder cancer[J ] . J Cell Mol Med, 2020, 24(1): 605-617. DOI: 10.1111/jcmm.14767.

DARWICHE F, PAREKH D J, GONZALGO M L. Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise[J]. Indian J Urol, 2015, 31(4): 273-282. DOI: 10.4103/0970-1591.166448.

LYDIATT W M, PATEL S G, OSULLIVAN B, et al . Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual[J ] . CA Cancer J Clin, 2017, 67(2): 122-137. DOI: 10.3322/caac.21389.

SHEN M, DUAN X Z, ZHOU P, et al . Lymphotoxin β receptor activation promotes bladder cancer in a nuclear factor-κB-dependent manner[J ] . Mol Med Rep, 2015, 11(2): 783-790. DOI: 10.3892/mmr.2014.2826.

MITTAL P, ROBERTS C W M. The SWI/SNF complex in cancer-biology, biomarkers and therapy[J]. Nat Rev Clin Oncol, 2020, 17(7): 435-448. DOI: 10.1038/s41571-020-0357-3.

COIRA I F, RUFINO-PALOMARES E E, ROMERO O A, et al . Expression inactivation of SMARCA4 by microRNAs in lung tumors[J ] . Hum Mol Genet, 2015, 24(5): 1400-1409. DOI: 10.1093/hmg/ddu554.

CHOI S A, KIM S K, LEE J Y, et al . LIN28B is highly expressed in atypical teratoid/rhabdoid tumor (AT/RT) and suppressed through the restoration of SMARCB1[J ] . Cancer Cell Int, 2016, 16: 32. DOI: 10.1186/s12935-016-0307-4.

ROBERTSON A G, KIM J, AL-AHMADIE H, et al . Comprehensive molecular characterization of muscle-invasive bladder cancer[J ] . Cell, 2017, 171(3): 540-556.e25. DOI: 10.1016/j.cell.2017.09.007.

SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551.

SIEVERT K D, AMEND B, NAGELE U, et al . Economic aspects of bladder cancer: what are the benefits and costs?[J ] . World J Urol, 2009, 27(3): 295-300. DOI: 10.1007/s00345-009-0395-z.

BERDIK C. Unlocking bladder cancer[J]. Nature, 2017, 551(7679): S34-S35. DOI: 10.1038/551s34a.

HOADLEY K A, YAU C, WOLF D M, et al . Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin[J ] . Cell, 2014, 158(4): 929-944. DOI: 10.1016/j.cell.2014.06.049.

WITTE T, PLASS C, GERHAUSER C. Pan-cancer patterns of DNA methylation[J]. Genome Med, 2014, 6(8): 66. DOI: 10.1186/s13073-014-0066-6.

BONASIO R, TU S, REINBERG D. Molecular signals of epigenetic states[J]. Science, 2010, 330(6004): 612-616. DOI: 10.1126/science.1191078.

SELVI R B, KUNDU T K. Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics[J]. Biotechnol J, 2009, 4(3): 375-390. DOI: 10.1002/biot.200900032.

COHET N, STEWART K M, MUDHASANI R, et al . SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells[J ] . J Cell Physiol, 2010, 223(3): 667-678. DOI: 10.1002/jcp.22072.

SENDINC E, JAMBHEKAR A, SHI Y. Remodeling your way out of cell cycle[J]. Cell, 2015, 162(2): 237-238. DOI: 10.1016/j.cell.2015.06.050.

SHAIN A H, POLLACK J R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers[J]. PLoS ONE, 2013, 8(1): e55119. DOI: 10.1371/journal.pone.0055119.

LIU F, XIA Z, ZHANG M, et al . SMARCAD1 promotes pancreatic cancer cell growth and metastasis through wnt/β-catenin-mediated EMT[J ] . Int J Biol Sci, 2019, 15(3): 636-646. DOI: 10.7150/ijbs.29562.

KAUFMANN B, WANG B, ZHONG S, et al . BRG1 promotes hepatocarcinogenesis by regulating proliferation and invasiveness[J ] . PLoS ONE, 2017, 12(7): e0180225. DOI: 10.1371/journal.pone.0180225.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expression of HMGCS2 and its correlation with clinopathological characteristics in bladder cancer

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Inhibitory effect of doxorubicin-loaded mesoporous silica nanoparticles on bladder cancer cells

Anti-tumor effect of mitochondrial targeted small molecule IR-780 on cisplatin-resistant bladder cancer cells

M2 macrophages promotes bladder cancer EMT through CLDN10 involved signaling pathway in tumor micro-environment

Related Author

Shuai ZHU

Yuheng WEN

Yu LIANG

Jian CAO

Kan LIU

Mingji YE

Yu XIE

Qingyue LIN

Related Institution

Department of Urology, Hunan Cancer Hospital, Affiliated Cancer Hospital to Xiangya School of Medicine of Central South University

Department of Respiratory Disease and Critical Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine

Department of Urology, the Third Affiliated Hospital of Chongqing Medical University

Department of Urology, Chongqing University Cancer Hospital

Center for Health Examination and Cancer Risk Screening, Chongqing University Cancer Hospital

⁰